FibroBiologics (NASDAQ:FBLG - Get Free Report)'s stock had its "buy" rating reiterated by investment analysts at HC Wainwright in a research report issued on Thursday,Benzinga reports. They currently have a $12.00 target price on the stock.
Other research analysts have also issued research reports about the company. D. Boral Capital reaffirmed a "buy" rating and set a $16.00 price target on shares of FibroBiologics in a research report on Friday, December 27th. Rodman & Renshaw began coverage on FibroBiologics in a report on Thursday, December 12th. They set a "buy" rating and a $12.00 target price for the company. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, FibroBiologics presently has a consensus rating of "Buy" and a consensus price target of $13.00.
Get Our Latest Stock Report on FBLG
FibroBiologics Price Performance
Shares of FBLG stock traded down $0.06 during mid-day trading on Thursday, reaching $1.23. The stock had a trading volume of 850,537 shares, compared to its average volume of 208,281. The stock's 50-day moving average price is $1.93 and its two-hundred day moving average price is $2.41. FibroBiologics has a 52-week low of $1.06 and a 52-week high of $15.50.
Institutional Trading of FibroBiologics
Hedge funds have recently modified their holdings of the business. Jane Street Group LLC grew its holdings in FibroBiologics by 415.3% in the fourth quarter. Jane Street Group LLC now owns 61,074 shares of the company's stock worth $122,000 after purchasing an additional 49,222 shares during the period. Raymond James Financial Inc. bought a new position in shares of FibroBiologics during the fourth quarter valued at $37,000. Cerity Partners LLC raised its position in shares of FibroBiologics by 49.9% in the 4th quarter. Cerity Partners LLC now owns 78,101 shares of the company's stock worth $156,000 after purchasing an additional 26,001 shares during the last quarter. O Shaughnessy Asset Management LLC purchased a new stake in shares of FibroBiologics during the fourth quarter valued at approximately $81,000. Finally, Virtu Financial LLC bought a new position in FibroBiologics in the 4th quarter valued at approximately $30,000.
FibroBiologics Company Profile
(
Get Free Report)
FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.
Recommended Stories
Before you consider FibroBiologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and FibroBiologics wasn't on the list.
While FibroBiologics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
